Current and potential use of GLP-1R agonists: beyond type 2 diabetes
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins have been developed. The results of GLP-1 and it...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2024-10-01
|
| Series: | Revista Mexicana de Endocrinología, Metabolismo y Nutrición |
| Subjects: | |
| Online Access: | http://www.revistadeendocrinologia.com/frame_eng.php?id=350 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846168431799304192 |
|---|---|
| author | Graciela Zambrano-Galván Ángel González-Romero Miguel A. Reyes-Romero Abelardo Camacho-Luis |
| author_facet | Graciela Zambrano-Galván Ángel González-Romero Miguel A. Reyes-Romero Abelardo Camacho-Luis |
| author_sort | Graciela Zambrano-Galván |
| collection | DOAJ |
| description | Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins have been developed. The results of GLP-1 and its pharmacological analogs are mediated by the GLP-1 receptor (GLP-1R), whose gene is mainly expressed in the pancreas, heart, and brain. They are used as second-line therapy in treating type 2 diabetes (T2D) due to their favorable effect on the glycemic profile and body weight. Current data suggest that GLP-1R agonists exert direct and indirect anti-inflammatory effects in treating T2D and, therefore, could also have clinical applications in other diseases with inflammatory components, such as T2D, non-alcoholic fatty liver and chronic inflammation present in aging and associated cardiovascular and neurodegenerative diseases, among others. A glance to these issues is the goal of this brief narrative review.
|
| format | Article |
| id | doaj-art-c25ef5cbde2849b68d042d5b5a2c69bd |
| institution | Kabale University |
| issn | 2462-4144 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Revista Mexicana de Endocrinología, Metabolismo y Nutrición |
| spelling | doaj-art-c25ef5cbde2849b68d042d5b5a2c69bd2024-11-13T22:01:50ZengPermanyerRevista Mexicana de Endocrinología, Metabolismo y Nutrición2462-41442024-10-0111410.24875/RME.23000053Current and potential use of GLP-1R agonists: beyond type 2 diabetesGraciela Zambrano-Galván0Ángel González-Romero1Miguel A. Reyes-Romero2Abelardo Camacho-Luis3Faculty of Medicine and Nutrition, Nutriepigenomics and Clinical Nutrition Laboratory, Food and Nutrition Research Center, Universidad Juárez del Estado de Durango, Durango, MexicoFaculty of Medicine and Nutrition, Internal Medicine Service, Universidad Juárez del Estado de Durango, Durango, MexicoFaculty of Medicine and Nutrition, Molecular Medicine Laboratory, Food and Nutrition Research Center, Universidad Juárez del Estado de Durango, Durango, MexicoFaculty of Medicine and Nutrition, Nutritional Physiology Laboratory, Food and Nutrition Research Center. Universidad Juárez del Estado de Durango, Durango, MexicoIntestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins have been developed. The results of GLP-1 and its pharmacological analogs are mediated by the GLP-1 receptor (GLP-1R), whose gene is mainly expressed in the pancreas, heart, and brain. They are used as second-line therapy in treating type 2 diabetes (T2D) due to their favorable effect on the glycemic profile and body weight. Current data suggest that GLP-1R agonists exert direct and indirect anti-inflammatory effects in treating T2D and, therefore, could also have clinical applications in other diseases with inflammatory components, such as T2D, non-alcoholic fatty liver and chronic inflammation present in aging and associated cardiovascular and neurodegenerative diseases, among others. A glance to these issues is the goal of this brief narrative review. http://www.revistadeendocrinologia.com/frame_eng.php?id=350Glucagon-like peptide 1 receptor. Incretins. Pharmacological glucagon-like peptide 1 receptor agonists. Type 2 diabetes. |
| spellingShingle | Graciela Zambrano-Galván Ángel González-Romero Miguel A. Reyes-Romero Abelardo Camacho-Luis Current and potential use of GLP-1R agonists: beyond type 2 diabetes Revista Mexicana de Endocrinología, Metabolismo y Nutrición Glucagon-like peptide 1 receptor. Incretins. Pharmacological glucagon-like peptide 1 receptor agonists. Type 2 diabetes. |
| title | Current and potential use of GLP-1R agonists: beyond type 2 diabetes |
| title_full | Current and potential use of GLP-1R agonists: beyond type 2 diabetes |
| title_fullStr | Current and potential use of GLP-1R agonists: beyond type 2 diabetes |
| title_full_unstemmed | Current and potential use of GLP-1R agonists: beyond type 2 diabetes |
| title_short | Current and potential use of GLP-1R agonists: beyond type 2 diabetes |
| title_sort | current and potential use of glp 1r agonists beyond type 2 diabetes |
| topic | Glucagon-like peptide 1 receptor. Incretins. Pharmacological glucagon-like peptide 1 receptor agonists. Type 2 diabetes. |
| url | http://www.revistadeendocrinologia.com/frame_eng.php?id=350 |
| work_keys_str_mv | AT gracielazambranogalvan currentandpotentialuseofglp1ragonistsbeyondtype2diabetes AT angelgonzalezromero currentandpotentialuseofglp1ragonistsbeyondtype2diabetes AT miguelareyesromero currentandpotentialuseofglp1ragonistsbeyondtype2diabetes AT abelardocamacholuis currentandpotentialuseofglp1ragonistsbeyondtype2diabetes |